Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MRUS 
Merus BV (MRUS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: MRUS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $90.38
1 Year Target Price $90.38
| 13 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 52.72% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.15B USD | Price to earnings Ratio - | 1Y Target Price 90.38 |
Price to earnings Ratio - | 1Y Target Price 90.38 | ||
Volume (30-day avg) 17 | Beta 1.19 | 52 Weeks Range 33.19 - 70.65 | Updated Date 09/16/2025 |
52 Weeks Range 33.19 - 70.65 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1250% |
Management Effectiveness
Return on Assets (TTM) -23.16% | Return on Equity (TTM) -48.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4563413629 | Price to Sales(TTM) 91.59 |
Enterprise Value 4563413629 | Price to Sales(TTM) 91.59 | ||
Enterprise Value to Revenue 81.16 | Enterprise Value to EBITDA -4.91 | Shares Outstanding 75634400 | Shares Floating 65608268 |
Shares Outstanding 75634400 | Shares Floating 65608268 | ||
Percent Insiders 2.29 | Percent Institutions 103.79 |
Upturn AI SWOT
Merus BV
Company Overview
History and Background
Merus BV is a clinical-stage immuno-oncology company developing innovative full-length multi-specific antibodies, referred to as Biclonicsu00ae and Triclonicsu00ae, for cancer treatment. Founded in 2003 in the Netherlands, it has focused on developing antibody-based therapeutics. Merus went public on the Nasdaq in 2016.
Core Business Areas
- Biclonicsu00ae Discovery and Development: Merus develops bispecific antibodies that simultaneously bind to two different targets. These antibodies are designed to engage the immune system and selectively kill tumor cells.
- Triclonicsu00ae Discovery and Development: Merus is also developing trispecific antibodies that engage three targets.
- Clinical Trials: Merus conducts clinical trials to evaluate the safety and efficacy of its antibody candidates across various cancer types.
Leadership and Structure
The leadership team includes individuals with expertise in oncology drug development and commercialization. The company has a board of directors overseeing the management team.
Top Products and Market Share
Key Offerings
- Zenocutuzumab (Zeno): A Biclonicsu00ae antibody targeting HER2 and HER3. Currently in clinical development for cancers with NRG1 fusions. No established market share yet as it is still in development. Competitors include companies developing therapies targeting NRG1 fusions, such as gene therapy and targeted small molecule inhibitors.
- Petosemtamab (MCLA-158): A Biclonicsu00ae antibody targeting EGFR and LGR5. Currently in clinical trials for solid tumors. No established market share yet as it is still in development. Competitors include companies developing therapies that target EGFR, which is a commonly used therapeutic method across various cancer treatments.
Market Dynamics
Industry Overview
The immuno-oncology field is experiencing rapid growth, driven by advancements in antibody engineering and cancer biology. There is increasing demand for novel cancer therapies that can overcome resistance mechanisms and improve patient outcomes.
Positioning
Merus is positioned as an innovator in the multi-specific antibody space, focused on developing differentiated therapies for challenging cancer targets. Competitive advantages include their Biclonicsu00ae and Triclonicsu00ae platforms.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is estimated to be in the hundreds of billions of dollars annually. Merus is targeting niche indications with high unmet needs, positioning them to capture a significant share of this market if their drugs are approved.
Upturn SWOT Analysis
Strengths
- Proprietary Biclonicsu00ae and Triclonicsu00ae technology platforms
- Experienced management team
- Pipeline of novel antibody candidates
- Strong intellectual property portfolio
Weaknesses
- Reliance on clinical trial success
- High research and development costs
- Limited commercialization experience
- Dependence on collaborations and partnerships
Opportunities
- Expansion of pipeline with new antibody candidates
- Strategic collaborations with larger pharmaceutical companies
- Approval and commercialization of lead drug candidates
- Potential for label expansions
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Changes in regulatory landscape
- Patent infringement challenges
Competitors and Market Share
Key Competitors
- JNJ
- BMY
- MRTX
- GSK
Competitive Landscape
Merus faces competition from larger pharmaceutical companies with established immuno-oncology franchises and from smaller biotech companies developing novel cancer therapies. Their competitive advantage lies in their multi-specific antibody platform.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by pipeline expansion and clinical trial advancements.
Future Projections: Future growth depends on the successful clinical development and commercialization of their antibody candidates. Analyst estimates vary widely based on the probability of success for their lead programs.
Recent Initiatives: Recent initiatives include advancing zenocutuzumab and petosemtamab through clinical trials and pursuing strategic collaborations.
Summary
Merus BV is a clinical-stage company with a promising technology platform. Their success hinges on the clinical trial outcomes of their lead candidates. Positive results could drive significant stock appreciation, while failures could negatively impact the company's prospects. They are currently holding steady in the competitive market but need positive clinical trial results to improve their marketability, partnerships and overall share of the market. The company should look out for rising R&D costs and competition from larger pharmaceutical companies
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data are estimates and may vary. Investing in biotechnology companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Merus BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-05-19 | CEO, President & Executive Director Dr. Sven Ante Lundberg M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 260 | Website https://www.merus.nl |
Full time employees 260 | Website https://www.merus.nl | ||
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.